2-Apr-2026
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
Globe Newswire (Mon, 16-Mar 7:00 AM ET)
Cronos Group Reports 2025 Fourth Quarter and Full-Year Results
Globe Newswire (Thu, 26-Feb 7:35 AM ET)
Cronos Launches New All-in-One Vape, Spinach PUFFERZ
Globe Newswire (Tue, 17-Feb 7:30 AM ET)
Globe Newswire (Thu, 12-Feb 7:30 AM ET)
Cronos Group Launches Premium Lord Jones Brand in Israel, Advancing Borderless Product Strategy
Globe Newswire (Mon, 2-Feb 2:30 PM ET)
Cronos Grabs Leading Share in European Cannabis With Strategic $67M Dutch Acquisition
Market Chameleon (Wed, 10-Dec 6:46 AM ET)
Cronos Secures Leading Position in Europe with $67 Million Acquisition of CanAdelaar
Market Chameleon (Tue, 9-Dec 6:10 AM ET)
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
Cronos Group - Common Share trades on the NASDAQ stock market under the symbol CRON.
As of April 2, 2026, CRON stock price climbed to $2.53 with 629,692 million shares trading.
CRON has a beta of 0.67, meaning it tends to be less sensitive to market movements. CRON has a correlation of 0.07 to the broad based SPY ETF.
CRON has a market cap of $968.84 million. This is considered a Small Cap stock.
Last quarter Cronos Group - Common Share reported $45 million in Revenue and $.00 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.
In the last 3 years, CRON traded as high as $3.43 and as low as $1.60.
The top ETF exchange traded funds that CRON belongs to (by Net Assets): DFIS, TOKE, DFIC, DFAX, ONEQ.
CRON has outperformed the market in the last year with a price return of +39.8% while the SPY ETF gained +17.5%. However, in the short term, CRON had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.3% vs -3.7% return in SPY. But in the last 2 weeks, CRON shares have fared better than the market returning +2.8% compared to SPY -0.1%.
CRON support price is $2.45 and resistance is $2.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRON shares will trade within this expected range on the day.
